Biocon Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Biocon wird ein jährliches Gewinn- und Umsatzwachstum von 2.9% bzw. 14.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 6.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.5% betragen.

Wichtige Informationen

2.9%

Wachstumsrate der Gewinne

5.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	47.2%
Wachstumsrate der Einnahmen	14.2%
Zukünftige Eigenkapitalrendite	6.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	17 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Recent updates

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Sep 20

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Jun 29

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Mar 28

Gewinn- und Umsatzwachstumsprognosen

NSEI:BIOCON - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	216,029	17,743	23,728	N/A	10
3/31/2026	185,033	12,790	22,493	N/A	17
3/31/2025	155,199	12,046	12,488	N/A	16
6/30/2024	147,660	15,808	N/A	N/A	N/A
3/31/2024	147,557	10,225	10,223	29,539	N/A
12/31/2023	146,125	12,002	N/A	N/A	N/A
9/30/2023	135,999	4,984	-6,241	11,717	N/A
6/30/2023	124,573	4,197	N/A	N/A	N/A
3/31/2023	111,742	4,627	1,262	18,525	N/A
12/31/2022	98,091	3,881	N/A	N/A	N/A
9/30/2022	90,422	6,170	-6,836	11,543	N/A
6/30/2022	85,629	7,084	N/A	N/A	N/A
3/31/2022	81,840	6,484	-7,482	11,766	N/A
12/31/2021	75,800	6,727	N/A	N/A	N/A
9/30/2021	72,632	6,542	-6,366	12,763	N/A
6/30/2021	71,726	6,852	N/A	N/A	N/A
3/31/2021	71,431	7,405	-5,866	11,597	N/A
12/31/2020	68,913	5,996	N/A	N/A	N/A
9/30/2020	67,571	6,362	-6,576	10,484	N/A
6/30/2020	65,796	6,870	N/A	N/A	N/A
3/31/2020	63,005	7,771	-5,534	12,831	N/A
12/31/2019	63,150	8,385	N/A	N/A	N/A
9/30/2019	61,077	8,529	-3,416	14,573	N/A
6/30/2019	58,565	9,919	N/A	N/A	N/A
3/31/2019	55,144	9,053	-3,374	11,546	N/A
12/31/2018	51,551	8,220	N/A	N/A	N/A
9/30/2018	46,722	6,967	N/A	N/A	N/A
6/30/2018	43,198	4,108	N/A	N/A	N/A
3/31/2018	41,234	3,724	N/A	6,621	N/A
12/31/2017	38,792	3,695	N/A	N/A	N/A
9/30/2017	38,589	4,489	N/A	N/A	N/A
6/30/2017	38,361	5,268	N/A	N/A	N/A
3/31/2017	38,911	6,121	N/A	6,400	N/A
12/31/2016	40,487	11,633	N/A	N/A	N/A
9/30/2016	38,110	10,961	N/A	N/A	N/A
6/30/2016	36,539	9,388	N/A	N/A	N/A
3/31/2016	33,474	5,504	N/A	3,706	N/A
12/31/2015	32,997	7,367	N/A	N/A	N/A
9/30/2015	32,325	7,247	N/A	N/A	N/A
6/30/2015	31,528	5,207	N/A	N/A	N/A
3/31/2015	30,898	4,974	N/A	2,107	N/A
12/31/2014	29,807	4,091	N/A	N/A	N/A
9/30/2014	29,168	4,231	N/A	N/A	N/A
6/30/2014	29,014	4,232	N/A	N/A	N/A
3/31/2014	28,773	4,138	N/A	5,607	N/A
12/31/2013	28,180	5,493	N/A	N/A	N/A
9/30/2013	27,510	5,361	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIOCONDas prognostizierte Gewinnwachstum (2.9% pro Jahr) liegt unter der Sparquote (6.7%).

Ertrag vs. Markt: BIOCONDie Erträge des Unternehmens (2.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (16.9% pro Jahr).

Hohe Wachstumserträge: BIOCONDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BIOCONDie Einnahmen des Unternehmens (14.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10% pro Jahr).

Hohe Wachstumseinnahmen: BIOCONDie Einnahmen des Unternehmens (14.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BIOCONDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.5 %).

Biocon Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 16%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Consensus forecasts updated

Recent updates

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

High number of new directors

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Upcoming dividend of ₹0.50 per share

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Investor sentiment improves as stock rises 18%

Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

New minor risk - Earnings quality

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Insider recently sold ₹1.1m worth of stock

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated

Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹13m worth of stock

Insider recently sold ₹40m worth of stock

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Insider recently sold ₹4.2m worth of stock

Consensus forecasts updated